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Abstract:
To enter the Chinese Pharmaceutical market, “Big Pharma” has adopted different strategies to tackle the
challenges specific to the country in terms of size, demographics, specific sales channels and logistics
adjustments. While the majority of Global Pharmaceutical players have opted for an aggressive M&A
approach to penetrate the Chinese market and gain local insight; the Danish Novo Nordisk has instead
chosen a strategy focusing on innovation and developing its R&D structure to capitalize on the local talent
pool. To illustrate Novo Nordisk’s growth strategy in the Mainland, we analyzed its competitiveness in the
diabetes market by demonstrating the key drivers behind this success. We applied a various set of tools for
this research: Novo Nordisk, Dong Bao Pharmaceutical executives’ interviews and personal observations
accounting for the primary data, we also reviewed secondary data to perform a PEST analysis in addition
to Porter’s competitive advantage model in order to extract the reasons behind Novo Nordisk’s marching
success in the Mainland.
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1. Diabetes Treatment Market in China
China recently became  the world capital of diabetes surpassing the United States for
patients diagnosed with either diabetes or pre-diabetes condition. A preliminary study
conducted in China by International Diabetes Federation estimates that the number of
people with diabetes in China has raised in excess of 92 million. The most prevalent
being type 1diabetes but there is an increasing threat of diabetes type 2 due to the major
changes the Chinese society has undergone these last 2 decades.
In 2007, China’s diabetes epidemic accounted for more than 14 percent of healthcare
expenditures  and  cost  the  country at  least  0.6  percent  of  GDP  in  lost  productivity,
according to the Economist Intelligence Unit (2007). They based their assessment on the
assumption that 4.3 percent of Chinese have diabetes, but new estimates place the rate at
around  10 percent,  meaning  that  the  costs  of  diabetes  on  China’s  economy  from
productivity losses are probably closer to 1.5 percent of GDP. Atop this, the International
Diabetes Federation estimates that in 2010, China directly spent around US$6.9 billion on
diabetes treatment (IDF, 2009). China’s diabetes problems highlight the twin challenges
of  chronic  diseases  stemming  from  changing  consumption  habits  enabled  by  China’s
economic boom and from the greying of its society, which is also a source of substantial
healthcare costs (Dong et al., 2011).
As China urbanizes and becomes wealthier, diets are shifting from the traditional rice and
vegetables and toward meats, sweets, and processed foods. In the past decade, per capita
sugar consumption in China has risen by 48 percent, according to the US Department ofVol. 5 ♦ Issue 2 ♦ 2013
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Agriculture. As in the U.S. and other countries, sweet beverages are a significant and
growing source of sugar consumption. Greater wealth has led to sweeping diet changes,
including eating heavily salted foods, fatty meats and sugary snacks — boosting obesity
rates, a major risk factor for Type 2 diabetes, which accounts for 90 percent to 95 percent
of all diabetes cases among adults.
It is estimated that by 2030, 40 million more will have the condition in China, where
diabetes causes 173.4 billion Yuan ($28 billion) a year in medical costs (Yang et al.,
2011). Prevalence of Type 2 diabetes has more than tripled in China over the past decade,
fuelling 20 percent-a-year growth in drug sales and straining health services.
A key difference is that an average of $194 a year is spent treating each diabetes patient in
China,  versus  more  than  $5,000  in  developed  countries  such  as  the  United  States
according to the International Diabetes Federation. Even as China’s health spending is
forecast to almost triple to $1 trillion over the next eight years, surging rates of diabetes
mean  China  is  struggling  to  detect  cases  and  provide  basic  care,  according  to  a
McKinsey& Company report (McKinsey & Co, 2012).
China’s pharmaceuticals market overall will increase 15-to-18 percent a year to reach as
much as $165 billion over the same period (Garber, 2012). It’s also stoking need for
newer, costlier medications from Merck & Co. (MRK), Novo Nordisk A/S (NOVOB) and
Sanofi that help avoid blood-sugar spikes and complications such as heart attack and
stroke. The  mainstay  diabetes  treatment  worldwide  is ‘Metformin’,  available  free  in
China  through  the  government’s  national  health  insurance  program.  Doctors  want  to
augment the 50-year-old pill with newer medicines, such as ‘Januvia’ from Merck, which
helps to stabilize blood-sugar, according to an April 2012 paper in the journal Diabetes &
Metabolism. ‘Victoza’, sold by Novo Nordisk, offers ‘minimum risk of hypoglycemia’,
according to company - sponsored research in the Lancet in 2010 (Green et al., 2003).
Merck’s ‘Januvia’ was approved for use in China in 2009 and costs 9.6 Yuan ($1.50) per 100-
milligram tablet, typically taken daily. Merck has applied to have the medicine added to China’s
National Drug Reimbursement List.
It takes as long as five years for a new product to be added to the reimbursement list,
McKinsey & Co. said in an August report. Addition makes it available to the masses and
can bolster sales, with 12 of the top 15 multinational drug makers deriving more than half
their  sales  in  China  from  subsidy- eligible  medicines. Some  provinces  of  China  are
introducing  their  own  pharmaceutical  subsidies  to  improve  affordability,  encouraging
drug makers to target markets outside major urban centres.
This encourages major the big Pharmaceutical players to move deeper into the country in
tier 2 and 3 cities and rural areas where the growth potential is exponential as it targets
unmet  needs  in  terms  of  healthcare  solutions  for  diabetes  due  to  lack of  healthcare
facilities and lower-incomes to afford a proper diabetes management scheme.European Journal of Interdisciplinary Studies
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2. Novo Nordisk in China - A long term commitment
“The rise of the Asian giants fundamentally changes the strategic landscape for MNCs”
(Hansen et al., 2010, p.11).
The  recent  crumbling  of  the  Euro  zone  economies with  debts  and  public  deficits  in
addition to the fiscal cliff in the USA all affected Chinese economy as its growth is tightly
linked  to  its  major  trade  partners. Despite  these  issues,  China  continues  to  witness
remarkable growth mainly due to its gigantic domestic market and it is expected that it
will have a stronger position vis-à-vis other countries after the crisis (Hansen et al. 2010).
The economic development and democratization witnessed in China  has had a major
impact on MNCs global strategies, as many cannot ignore the vast market opportunities it
represents in terms of size and specific needs.
In addition, China’s industrial development has affected the global competition, putting
pressure on  global  players (Novo  Nordisk, 2009). The  Pharmaceutical  industry  is  no
exception to this trend, as the biggest pharmaceutical companies see the appeal of China,
not only because of its market size, but also thanks to the R&D innovation opportunities it
can offer at lower costs than in the West. That is if, the global companies such as major
pharmaceutical companies manage to tackle the challenges of opting for the right entry
strategy and find optimal sales channels to pave its way deep inside the rural areas in
China.
The booming economy in the Mainland China during the last two decades has enticed
several  countries  like  Denmark  to  tap  this  market  and  play  an  active  role  in  it.  The
following factors have accelerated this trend:
1. Liberalization of requirements for foreign investors
2. The establishment of Special Economic Zones (SEZ)
3. Large reductions in tariffs
4. Investments in infrastructure
5. Rapidly growing purchasing power. (Hansen et al., 2010, p.13)
Thus,  recent  development  both  on  a  global  level  and  in  China  has  increased and
diversified the Danish involvement in China in order to understand the market in the
Mainland and acquire the flexibility to adapt to local demand (Brødsgaard et al., 2000).
One of the heavy weights of the Danish industry, the pharmaceutical company Novo
Nordisk made its first move in the Mainland in 1962 where it introduced its first product
line, but the real first decisive step was taken in 1994 where the Danish Pharmaceutical
giant opened its first sales office - The Novo Nordisk Beijing Co. Ltd - and initiated the
production there in 1996. The main reasons to enter the market then were the cheaper
labour costs and the size of the local market, it moved its production facilities to Tianjin
Economic  development  Area  (TEDA)  to  benefit from  lowered  taxes  and  improved
infrastructures.
Novo Nordisk keeps expanding its operations and its involvement in the country with a
specific emphasis on R&D efforts in the last years through investments and infrastructure
development  in  their  Tianjin  facilities. When  making  such  operational  changes,  the
Danish company chose to lower its operating costs by relocating to Tianjin but at the
same  time  ensured  the  continuity  it  terms  of  quality  and  safety  that  Pharmaceutical
products require by bringing its own global quality standards to China. Its good working
conditions  also  made  it  easier  for  the  company  to  ensure  a  lower  turn-over  of  theirVol. 5 ♦ Issue 2 ♦ 2013
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employees and has raised its local productivity in China with the various benefits it offers
its staff in the Mainland (Birkmose and Popovici, 2011).
Table1. Timeline of Novo Nordisk’s commitment to changing diabetes in
China
Year
2012  First batch of Penfill from Filling plant Tianjin
2012 - 2011  China independent region
2010  Shared service centre
2009  NovoPen® 4 manufactured in China only
 2nd Public-private partnership with Ministry of Health: Hospital community
 integrated diabetes education program co-funded by WDF and Novo
Nordisk
 Executive hospital managers MBA programme
 Three research partnerships
 Diabetes leadership forum 2009 China (Public affairs)
2008  Chemical compound library licence to National centre for drug screening
 Changing diabetes®, 60 Cities tour
 Cornerstone set for DKK 4000 million filling plant
2007  Partnership with Chinese Academy of Sciences a Research Foundation
 Clinical development centre Beijing
 DMDP - expanding diabetes care to smaller cities
2006  Changing diabetes bus
 Major expansion of Novo Nordisk Tianjin Plant
 Complete transfer of NovoPen® 3
2005  Health-Star search involves General public
2004  Expansion of packing and warehousing
2003  1st Public private partnership with Ministry of Health: National diabetes
 program funded co-funded by World Diabetes Foundation and Novo
Nordisk
 Novo Nordisk Tianjin Plant: First NovoPen® 3 released
2002  Novo Nordisk Diabetes Update for physicians
 Inauguration of R&D centre, Beijing
2001  Novo Care club education team
 Launch of STAR diabetes training with Steno Diabetes Center
1995  Opens Production facility, Tianjin
1994  Novo Nordisk Biotech Co., Ltd, Beijing
1962  Introduces the first line of products in China
Source: Novo Nordisk (2011): The Blueprint for Change ProgramEuropean Journal of Interdisciplinary Studies
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3. The Driving Forces behind Novo Nordisk’s Success in China
3.1. Chinese macro environment
China reunites the perfect macro environment for Novo Nordisk to thrive and further
expands  its  presence  in  the  mainland. The  country presently  offers  several  political,
economic, legal and socio-demographic factors in favour of the expansion of innovation
driven enterprises whether local or foreign.
3.1.1. Political environment
The 12
th 5 year plan has been marked by a strong emphasis on innovation, in order to
transform China from the low-end products manufacturers to one of the leaders in science
and technology producing high-end goods for both an ever growing domestic market and
a global market (Miura, 2013). Xi Jin Ping has also recently emphasized the need for
China to develop its talent pool and its high-technology focused industries in order to
remain  competitive  on  global  scale  and  ensure  a  sustainable  development  for  the
upcoming generations (China Daily, 2013).
Recently, the Chinese Manufacturing sector that helped the country’s economy expand at
an  astonishing  pace  in  the  last two decades  is  now  facing  a  major  crisis  with  the
increasing  costs  of  raw  materials  worldwide,  and  the  rising  competition  from
neighbouring countries with cheaper labour costs such as: Cambodia, Bangladesh. China
is transitioning from industries like textile or mass electronics and heading towards more
complex industries with a stronger focus on R&D. This policy is already paying off with
China becoming one of the top three manufacturers of API in the world (KPMG, 2011).
One other important aspect of the government’s support for Pharmaceutical sector is the
comprehensive healthcare reform initiated in 2009. This reform has been set to close the
gap between rural and urban health by widening the healthcare coverage throughout the
Chinese territory. In addition, this new set of laws and regulations aim at providing a
better, more accessible and affordable healthcare service to its population and achieve a
total healthcare coverage by 2020.
3.1.2. Legal environment
China  has  introduced  a  set  of  laws  and  tax  incentives  to  boost  innovation  and  work
towards achieving the goals of its health care reform initiated in 2009. Among the most
relevant  laws  and  regulations  we  find  The  Anhui  model. This  new  set  of  laws  and
regulations  compiled  in  the  Anhui  model  represents  an  aggressive  tendering  system
enforced by the Chinese government that resulted in the slash of drug prices by at least
30% of key drugs (part of the essential drugs list). Although this reform has resulted in
the shrinkage of the profit margin of these companies they are still profitable and this
reform  would  eventually  be  profitable  in  the  long  term  for foreign pharmaceutical
companies as it will drive demand up resulting in growth through the increase of sales
volume. This would benefit Novo Nordisk as it capitalizes its growth strategy in the
country by increasing its sales volume and market share in a sector that witnesses an
exponential growth, namely the diabetes market in China.
In addition to the Anhui Model, the government has enforced a series of regulations and
laws in favour of the development of innovation oriented enterprises. Hence, the new
Company Income Tax Law introduced in January 1
st 2008 that provided tax incentives to
boost R&D and gave preferential income tax rates in addition to turnover tax exemptions
for R&D centres providing research services to overseas companies (Eggleston et al.,Vol. 5 ♦ Issue 2 ♦ 2013
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2008). Pharmaceutical manufacturers are eligible for reduced income tax rate if these
enterprises qualify as “Advanced & new technology enterprise” which is in the same line
as HNTE incentive standing for High New Technology Enterprise being taxed at the
preferential rate of 15 percent instead of the standard 45 percent. This adds up to the other
tax incentives such as the ones in the SEZ within Mainland in addition to technology
incubators such as TEDA in Tianjin where Novo Nordisk pursues its R&D efforts and
enjoys lower taxes.
1.1.3. Socio-demographic environment
In recent years it has been estimated that the current global prevalence of type 2 diabetes
amounts to about 150 million patients. Projections suggest that by the  year 2025 the
number of prevalent patients in the world will reach approximately 300 million. It is
assumed that the increase in the number of patients will be most pronounced in nations
currently  undergoing  socio-economic  development  including  increasing
urbanization. Urbanization  has  been  linked  to  obesity  and  its  consequences  on  the
individual’s health deterioration.
The  rapid  economic  development  has  changed  of  the  Chinese  society  to  the  core,
transitioning to a more sedentary population with a higher buying power able to afford
more food products. Combining these factors with the increased carbohydrates intake per
person in China through the profusion of fast-food options within big cities and with lack
of  physical  activity  have  resulted  in  a  society  exposed  to  the  threat  of  diabetes  and
metabolic disorders which will further increase the burden of healthcare spending of the
Chinese government.
China's large population and rapid economic development have made it an epicentre of
the epidemic. Asian populations tend to develop diabetes at younger ages and lower BMI
levels  than  Caucasians.  Several  factors  contribute  to  accelerated  diabetes  epidemic  in
Asians, including the ‘normal-weight metabolically obese’ phenotype; high prevalence of
smoking and heavy alcohol use; high intake of refined carbohydrates (e.g., white rice);
and dramatically decreased physical activity levels. Poor nutrition in-utero and in early
life combined with over nutrition in later life may also play a role in Asia's diabetes
epidemic. Nonetheless, interactions between Westernized diet and lifestyle and genetic
background  may accelerate  the  growth  of  diabetes  in  the context  of  rapid  nutrition
transition (Hu, 2011).
The current development of the Chinese society, especially in urban areas have resulted in
a  more  health-conscious  society,  as  this  fringe  of  the  population  tends  to  be  more
educated and increasingly aware of the risks it is exposed to health wise. Compounded by
growing disposable incomes and consumer preference for safe and quality products, these
factors are driving the growth of China's health and wellness market.
Denmark’s  reputation  among  Chinese  citizens  as  a  country  with  a  clean  and  green
environment and an unequalled food safety record might mean that Danish products may
already  have  an  advantage. This  contributes  to  driving  drug  sales  up  in  the  country;
China’s over-the-counter market is growing fast and has become the fourth largest OTC
market in the world. Foreign enterprises have been closely monitoring the expanding
OTC  market. Merck announced  the  launch  of  OTC  program  in  China  in  September
2003. Roche listed China as one of its 10 core OTC markets, with the aim of growing its
OTC  drug  sales  by  50 percent in  the  next  five  years  and  reaching  1.3  billion  in
2008. Novartis is expanding its OTC market share in China, and Wyeth has also entered
OTC market.European Journal of Interdisciplinary Studies
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1.1.4. Technological environment
China is increasingly relying on a growing local talent resulting from heavy investment in
higher education and exchange programs with universities abroad. The number of PhD
degree holders and scientists has been increasing steadily and China ranks among the top
3 publishers of scientific articles in the world. In addition, the mainland starts capitalizing
on  the  ‘brain  gain’  through  the  Chinese  returning  from  overseas  attracted  by  the
dynamism of Asian economy and the benefits reaped from their rise on the global scale
(Simon and Cao, 2008).
This trend has been integrated in Novo Nordisk’s expansion strategy. Instead of the sole
reliance on their R&D centres in Denmark, Novo Nordisk has decided to relocate its
R&D operations in Tianjin to fully utilize the local talent pool and nurture it locally by
providing infrastructures equipped with the latest technologies and a close collaboration
and synergy between its different R&D centres worldwide.
Another major asset China could benefit from is the modernization and integration of
Traditional  Chinese  Medicine  (TCM)  to  Western  Medicine  to  achieve  new  drug
development. GlaxoSmithKline Plc is testing botanicals compounds extracted from plants
for immune disorders, Sanofi plans to turn traditional Chinese medicines into alternative
diabetes and cancer therapies, and Nestle SA teamed last month with billionaire Li Ka-
Shing to develop a drug derived from ancient Chinese approaches to cure inflammatory
bowel disease.
The confluence of China’s growing middle class and the drought of Big Pharma pipelines
crystallized for them the need to integrate Western drugmakers the 2,500 year-old form of
medicine they once scoffed at. (Gao et.al, 2007).
3.2. Internal drivers to Novo Nordisk’s success in China
According to Novo Nordisk China’s former senior executive “Time, money, experience
and efficiency” are the key determinants for Novo Nordisk’s success in the Mainland. For
him, Novo Nordisk has been here longer than most other Pharmaceutical Multinationals,
they have been more involved in the country, they have hence accumulated a wealth of
knowledge and experience in China and they had and still have the financing to back
aggressive growth.
3.2.1. First mover advantage
The motivations for Novo Nordisk appear to be largely related to the increasing size and
importance of the Chinese market as China is set to take the lead and become the leading
economy in the world by 2050 (Harksworth, 2006). A long-term and holistic approach is
emphasized, which is supported by their development in terms of commitment in China.
This success may be due to the first-mover advantage achieved by being present in China
for decades and furthermore by Novo Nordisk’s recognition of the importance of local
government collaboration (Tellis, 1993). This have earned the company the precious edge
over its competitors to deeply penetrate the Chinese market and get valuable knowledge
about the changes the country has undergone in the last four decades (Bakerma et al.,
1996).
In  addition,  the  strategy  of  Novo  Nordisk  in  China  has  been  characterized  by  their
supporting  roles  to  their  business,  e.g.  the  training  of  pharmacists  and  awareness
campaigns / patients’ education programs, the extensive work benefits to attract, motivate
and retain a sustainable and productive workforce (Wang and Boel, 2006). These trainingVol. 5 ♦ Issue 2 ♦ 2013
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programs and consumer education have been essential – also due to Novo Nordisk being
one of the first players in the Chinese market (Lasserre, 2007), we can conclude in this
case the first-mover approach appears to have been beneficial for the Danish pharma
giant.
In  addition  to  its  early  entry  to  the  Chinese  market  in  the  1990s,  Novo  Nordisk
distinguished itself from the other pharma giants by opting for a holistic approach with an
emphasis on R&D and innovation within its Chinese headquarters. Whereas, most of the
other Pharmaceutical Multinationals have chosen the aggressive M&A strategy buying
out local Chinese pharma manufacturers to capitalize on their market knowledge and their
sales channels in urban but more importantly in tier 2, 3 cities and rural areas which still
represents the Achilles heel of pharma giants in the country (Kang et al., 2009).
Through  its  differentiation  and  shift  in  focus,  Novo  Nordisk’s  strategy  is  paying  off
especially to capture the lion’s share in the Diabetes market in China. By 2010, Novo
Nordisk had an impressive 63% market   in China, and the country represents its third
biggest market (Novo Nordisk, 2011).
Figure 1. Opportunities created by the external and internal environment of
Novo Nordisk in China
Source: own conceptualisation
As we can see from Figure 1, the Danish pharma giant is actually benefiting from a series
of factors. Novo Nordisk products have been present in China since 1962. In 1994, an
affiliate was established and a long-term strategy for diabetes in China was crafted. The
first production facility was opened in 1995 in Tianjin – a packaging site. In 2002, Novo
Nordisk opened a research and development centre in China, the first pharmaceutical
company  to do  so.  In  2003,  the  company  began  transferring  the  production  of  their
NovoPen  3,  an  insulin  device,  to  Tianjin.  By  2009,  NovoPen  3  and  its  successor,
NovoPen 4, were entirely produced in China. In 2008, Novo Nordisk began constructing
a new plant that will produce insulin filling in Tianjin. The company estimates that the
plant will start production in 2012. By 2015, Novo Nordisk expects to have built the
entire facility range in order to serve the Chinese market.
Novo Nordisk products had been present on the Chinese market for 32 years, when the
company opened an affiliate named Novo Nordisk Biotech in Beijing in 1994. One year
later,  the  first  production  facility  opened  in  Tianjin.  In  2002,  the  research  and
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development centre also opened in Beijing. This helped the Danish company establish
their pioneer position in China which earned them a preferential access to the market and
helped them set up strategic partnerships with various actors of the industry at different
levels: policy makers, local manufacturers, healthcare providers and of course patients.
Throughout these 50 years, Novo Nordisk has acquired a deep knowledge of the Chinese
market and its evolution throughout the years. Hence, it has been quickly reactive to the
Chinese social structure changes and lifestyle transformation for the local population and
its  impacts  on  their  health. It  also  earned  the  trust  of  the  Chinese  government  by
delivering  quality  products  and  being  involved  in  sponsoring  national  prevention
campaigns that turned out to be a win-win for both parties. It increased and still increases
the awareness of diabetes in rural China and other remote areas which have little or no
access at all to healthcare facilities or healthcare professionals to inform them, educate
them and screen the disease’s incidence to better manage it and avoid the complications
related to the affection.
Novo Nordisk plans to tackle diabetes in China on several fronts. Due to the complexities
of the disease, a combination of measures is necessary. On the one hand, physicians need
to  be  engaged  and  informed  about  medicine.  On  the  other  hand,  patients  have  to  be
informed about diabetes management. According to the company’s website, a holistic
strategy  is  required – one  that  focuses  on  “physician  training,  patient  education,
strengthening the healthcare system, public awareness, local production and R&D” (Novo
Nordisk, 2011).
Novo Nordisk engaged the World Diabetes Forum and the Chinese Ministry of Health to
create  the  National  Diabetes  Program,  which  consisted  of several  private-public
partnerships  focused  on  health  system  integration  and  educating  both  physicians  and
patients. The  approach  used  with  medical  staff  focused  on  “prevention,  screening,
optimizing treatment and patient communication” (Novo Nordisk, 2011). Around 55,000
doctors  participated  in  a  series  of  seminars  and  conferences  with  leading  diabetes
researchers around the world. The participants ranked the training as very important in
improving  the  relation  with  their  diabetes  patients. Novo  Nordisk  estimates  that  its
programs  reached  and  educated  around  280,000  patients  since  1997.  Such  programs
include  the  Novo  Care  hotline,  which  connects  patients  with  diabetes  management
specialists, or The Changing Diabetes Bus, which provides mobile education to various
communities. Patient education increases sales by DKK 3,400 per patient.
Finally,  local  production  and  R&D  has  given  the  company  greater  flexibility  and  a
quicker response time. Novo Nordisk uses a range of suppliers from China (Tianjin and
Shenzhen) and from Thailand, which adds to the benefit of producing in this region.
China is currently the third biggest market for Novo Nordisk. In 2010, their market share
was 63%. In addition, Novo Nordisk created 14,600 jobs, directly and indirectly.
3.2.2. Global Innovation rather than the M&A approach in China and globally
Rather than focusing on a M&A strategy to reinforce its presence in the country, the
company  focuses on innovation and make considerable R&D investments using local
talent working in state-of-the-art facilities in Beijing and Tianjin to get the full potential
of the existing talent pool in China. In addition, the company is also heavily involved in
prevention and information campaigns targeting healthcare personnel and patients to raise
awareness about a disease that is set to become a burden for the country’s healthcare
spending in the upcoming years considering the socio-economic factors characterizing
China.Vol. 5 ♦ Issue 2 ♦ 2013
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The fine slicing of the value chain (Buckley and Ghauri, 2004) can be a risky procedure,
given  the  increasing  cost  of  transportation  and  general  transfer  costs.  However,  the
pharmaceutical industry seems to be remarkably adept at this practice, partially because
of the lengthy and complex research process. In fact, research and development is the area
most  prone  to  slicing.  Yale  Global  Online counts  as  many  as  18  steps  that  can  be
undertaken and thus outsourced during research (Contractor, 2010). Some of these steps
are  highly  sensitive – genetics,  phase  0  and  phase  1  clinical  trial,  in  addition  to
administrative steps such as regulatory measures. They are normally undertaken in the
research centre pertaining to HQ. Others, such as IT-related matters, can be easily off
shored to companies in traditional outsourcing nations. Medium-level processes can take
place offshore, on the sites of subsidiaries or of affiliates.
While there are advantages to fine slicing, the coordination costs can be daunting. One
must  also  take  into  account  the  degree  to  which  information  needs  to  be  coded  and
communicated across sites and internalized within the company. Vernon’s product life
cycle can be called into question when analyzing Novo Nordisk’s case. The old model is
being challenged, since emerging markets are no longer imitators, but innovators on their
own. In this case, Novo Nordisk is not simply relocating the manufacturing of mature
products in China, but moving research altogether. However, it is important to notice that
it is still an advanced country company that runs the operations and not a local one. The
benefits  to  the  local  economy  are  highly  dependent  on  linkages,  as  are  knowledge
spillovers and the learning process.
Novo Nordisk’s research centre is found in Beijing, where 60% of R&D facilities in
China is located (Zhou, 2004). The company can thus take advantage of a research cluster
and can integrate into a global R&D network. The advantages of such a situation are
learning, access to low-cost and fine quality scientists and quicker responses. However,
there  are  also  disadvantages,  such  as  critical  mass  constraints  and  communication
constraints.  In  the  case  of  China,  it  is  perhaps  premature  to  claim  overcrowding  of
laboratories and research sites. Communication constraints can remain a problem; still,
Novo Nordisk is aiming to integrate the Chinese zone, which means that the research
centre in Beijing will connect primarily to the plant in Tianjin (Buckley et al., 2004).
While the company as a whole can be described as a value chain, its intensive technology
activities qualify it as a value shop (Stabell and Fjeldstad, 1998). In the case of the value
shop, the company’s resources are used to find solutions to a particular problem. With a
value  chain,  the  purpose  is  achieving  economies  of  scale  with  relatively  standard
products.
As it was mentioned in the case, diabetes in China follows an entirely different dynamic
than in the industrialized countries. It can be inferred that the problem is unique and needs
a special, localized solution – hence, local research. In addition, Novo Nordisk tackles
these  new  challenges  through  its  parallel  physician  training  programs  or  through  its
patient education measures. One of the main characteristics of the value shop is that there
are limited advantages in dealing in large volumes – location is much more important.
(Stabell et al., 1998). Given the rise of diabetes in Asia, it is possible that Novo Nordisk
will combine the two concepts: treat a disease with Asian lifestyle specificities, from an
advantageous position, but in large numbers and possibly even achieving economies of
scale.
3.2.3. Novo Nordisk’s local commitment in China
Novo Nordisk claims that “although the Chinese culture is significantly different fromEuropean Journal of Interdisciplinary Studies
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that of the West, there is no major cultural barrier for success of a Western style R&D
organization in China, because Chinese employees are amenable to changes” (Wang and
Boel, 2006). However, this statement indicates two things; firstly, that Novo has made a
cultural  observation  in  terms  of  the  Chinese  employees  being  open  to  change  and
secondly, Novo Nordisk has employed resources for training of their employees. This
could indicate that Novo Nordisk has been successful in terms of creating an environment
which suits the Chinese culture, e.g. though clear objectives (ibid.). Additionally, Novo
Nordisk emphasizes that their management style is rooted in Chinese traditions. This
example entails recognition of accomplishments and clear orders (ibid.).
In terms of both team work and innovation, Novo Nordisk has met some challenges in
their Chinese operations. As team-work is not customary in the Chinese culture, but it is
crucial for the working processes of Novo; therefore, the local management teams have
been given the task to motivate team work. Novo has found that there is a low level of
PhD  training  in  innovation  in  China,  which  represents  a  challenge  for  an  innovation
focused  company.  However,  Novo  sees  great  potential  which  may  be  exploited  by
bringing in western scientists.
Local impact and socioeconomic improvements are high on the list of priorities for Novo
Nordisk, in addition to seeing a huge business potential in China (Novo Nordisk, 2004)
“Diabetes poses a growing social, educational and economic challenge for the Chinese
society and the people and families affected by diabetes. An estimated 40 million people
in China have type 2 diabetes in 2010, a number expected to reach 80 million over the
next 15 years” (Novo Nordisk, 2011).
When presenting its operations in China, Novo Nordisk, thus, has great emphasis on the
CSR aspects, such as local job creation, strengthening the health care system and the
education of employees (ibid.). This correlates well with China’s status as a developing
country, with insufficient institutions and infrastructure (Hansen et al., 2010). In order for
Novo Nordisk to be successful, it is highly relevant for the company to train the scientists
and educate the consumers, and its positive impacts on the Chinese society  not only
creates legitimacy but also represents a great importance in regards to the relationship
with the Chinese governments and society. Proof of Novo Nordisk preferential position in
China, Recently Eli Lilly and Sanofi have both been asked by the Chinese government to
lower  prices  on  some  of  the  products  in  their  diabetes  lines,  though  Novo  Nordisk
escaped this unscathed.
3.2.4. Financial resources
Novo Nordisk raised its full-year sales and profit forecasts after reporting second-quarter
earnings that beat analysts’ estimates. The shares rose to a record. Revenue will jump 9
percent to 12 percent this year in local currencies, compared with a previous forecast for
an increase of 8 percent to 11 percent, the Bagsvaerd, Denmark-based company said.
Operating-profit growth in local currencies will be about 15 percent, compared with a
previous prediction of at least 10 percent.
Having secured a steady growth rate, the company has hence decided to reaffirm its long-
term commitment to China by investing an additional 100 million US dollars to expand
its state-of-the-art science facilities in Beijing. The new 12,000m
2 centre will make it
possible to increase the number of science employees from the current 130 to 200, with
extra  space  available  to  accommodate additional  future  growth.  With  this  expansion,
Novo Nordisk also fulfils its key strategic objective to ensure the full range of protein
research capabilities in China (Deloitte, 2013).Vol. 5 ♦ Issue 2 ♦ 2013
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Figure 2.The key drivers behind Novo Nordisk’s growth in China
Source: own conceptualisation
Analysts  point  that  the  site  in  Beijing  has  already  contributed  significantly  to  the
company’s research and development portfolio in both diabetes and biopharmaceutical
target disease areas. The new, expanded facility will enable even stronger contributions
from the science team in China across the range of Novo Nordisk’s protein technology,
biology and pharmacology research activities. The main focus of Novo Nordisk in China
therefore differs from its other competitors.
4. Findings
From the data collected through the various sources and the personal observations we
could  deduct  the  reasons  behind  the  Novo  Nordisk’s  success  in  the  Chinese  Market.
Using  Porter’s  diamond  of  National  competitive  advantage  applied  to  the  Chinese
diabetes market we can observe the following (see Figure 3):
Figure 2.Porter’s Diamond of National Competitive Advantage for Novo
Nordisk in China
Source: own conceptualisation
We can deduct from Figure 3 above the main factors that lead Novo Nordisk to gain
competitive edge over its competitors in the diabetes market landscape. The focus on
innovation and emphasis on R&D in China differentiates the Danish group from its other
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”Big Pharma” counterparts opting for consolidation through a series of M&A activities in
the Mainland.
The Danish pharmaceutical giant has proven to be in possession of the necessary financial
resources to set up state-of-the art facilities in the Asian continent to spur innovation in
the  field.  It  has  also  gained  a  consequent  advantage  by  gaining  valuable  market
knowledge by setting their operations in China before any of their foreign competitors
which saw in China a sole outsourcing destination rather than a real market to seize until
recently. It has spent consequent efforts to ‘Glocalize’ the company’s in the country by
adapting  to  the  market’s  specific  needs  in  terms  of  treatment,  hiring  local  talent  and
blending corporate values with the local cultural values and beliefs that would serve the
company’s  productivity  and  competitiveness  in  the  Chinese  market  (Bakerma et al.,
1996; Johansson, 2006).
Novo Nordisk has also benefited of the thrive of supporting industries in the country as
the China is one of the major API manufacturers on one hand and actively supports the
development of CROs and biotechnology companies in high-technology parks acting as
incubators for innovation in the industry across the country.
The  Danish  Pharmaceutical  company also  benefits  from  the  government’s  ties  it  had
established by showing its commitment to the country decades ago and hence yielding the
results of those previous efforts by escaping the drug price slashing wave that hit many
Pharmaceutical companies  following  the  Anhui  Model  reform.  Especially  since  the
government has launched a series of healthcare reforms to achieve universal coverage by
2020. This helped spur the demand for better healthcare service and hence better solutions
to manage diabetes in the country. The rising purchasing power of their ever increasing
urban, educated middle class and its increased awareness about health issues is creating
new sustainable market opportunities for Novo Nordisk in the Mainland.
5. Conclusions and Recommendations
According to a new market report published by “Transparency Market Research”, the
global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is
expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to
2018. In the overall global market, North America accounted for the highest share worth
USD 19.9 billion in 2011 followed by Europe. However, with the continuous population
and  economic  growth  of  the  Asia-Pacific  region,  especially  India  and  China,  it  is
expected to witness the highest growth rate in the next six years. This shows the growing
importance of the Chinese diabetes market that will further increase in the upcoming
years due a combination of an ageing population, a rising urban population and changes
in diets and lifestyle that are all in favour of a rapid development of pre-diabetic and
diabetic conditions.
The healthcare reforms, the rapid socio-demographic changes transformed the Chinese
drug  market  from  a  tertiary  one  to  the  fastest  growing  in  the  world  and  it  is  set  to
represent the biggest diabetes market by 2020.
Novo Nordisk stands out from the other big pharmaceutical companies in the country
with its long term commitment to the country benefiting from the first mover advantage
in the diabetes market. This helped them build solid ties with the government ever sinceVol. 5 ♦ Issue 2 ♦ 2013
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and had the privilege of partnering with the highest authorities in their efforts to tackle the
diabetes in China throughout the sponsoring of prevention and treatment campaigns.
When  other  big pharmaceutical  companies are  still  opting  for  aggressive  merger  and
acquisitions as their dominant entry strategy into the Chinese pharmaceutical market, the
Danish giant has shifted its focus on innovation to benefit from the local R&D potential
and at the same time lower the costs of drug research and speed up the discovery process,
it has implemented this strategy  by joining forces with local partners in academia and
local research facilities to support their state-of-the-art R&D facility in Tianjin.
Novo Nordisk is benefiting from its pioneer’s position in the diabetes market in China
(First mover’s advantage) but has also taken advantage of the macro environment factors
that are helping to leverage its growth in the country. Most prominent factors being the
country’s new focus on innovation, and development being in line with Novo Nordisk’s
overall growth strategy in the Mainland not only relying on foreign expertise but also
increasingly using the local talent pool. The choice to set their R&D center in Tier II city
in China (Tianjin), not only illustrates their strategy to lower operating costs but also to
localize  their  efforts  in  the  country  by  hiring  local  talent  and  leveraging  the  R&D
capabilities in that region and therefore get additional support and incentives from the
government for making such decisions.
China will also provide an increased diabetes market share for the Danish giant as the
socio-economic factors are pushing the number of pre-diabetic and diabetic patients up in
the Mainland and a set of external factors in the country will drive the sales growth
considering the westernization of the lifestyle in China, the healthcare reforms and the
rising awareness about health issues such as Diabetes (Hitt et al., 2003).
The combination of an early entry into the Chinese market, their reactivity to the changes
undergone by the country on a political, socio-economic level that lead them to switch
from the outsourcing destination mindset to the establishment of a local R&D hub in the
region  to  cater  for  the  specific  needs  of  the  local  market  make  Novo  Nordisk  gain
competitive advantage for the diabetes market in China.
The future battleground for “Big Pharma” will be the ability to penetrate tier II, tier III
and rural areas in China where local Pharmaceutical manufacturers such as Dong Bao
who controls 10% of the human recombinant insulin market in China and Shanghai Fosun
are growing quickly in these remote areas thanks to well established sales channels and
deep market knowledge that is still lacking in “Big Pharma”.
This is particularly the case for supply lines settings ,due to the country’s size and various
logistical and geographical barriers especially in Western China make these supply lines
problematic to establish and maintain and that is where local manufacturers still have the
upper hand but we speculate that it will be just a matter of time before big Pharmaceutical
companies tackle this issue considering the importance of the Chinese market in the near
future and its role in providing sustainable growth for Pharmaceutical giants.
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